NANOBIOTIX Responds to Media Speculation on Takeover Intentions

On March 25, 2026, NANOBIOTIX, a biotechnology firm focused on nanotherapeutic approaches, addressed recent media rumors about a potential public takeover. According to the company, there are no plans or ongoing processes regarding such an acquisition. The company also noted inaccuracies in the media report, which contradict their latest public disclosures.

Nanobiotix, listed on Euronext and NASDAQ, emphasized that, to its knowledge, no takeover intentions exist. It remains focused on its ongoing projects and the potential expansion of treatment options for cancer and other diseases using their proprietary nanotechnology platforms.